Nano-engineered therapeutic stealth cells

Therapeutic stealth cells, engineered to enhance motility and deliver drugs, address the limitations of current techniques by targeting and destroying recurrent tumor foci, thereby reducing treatment resistance and recurrence in glioblastoma multiforme.

JP2024156704APending Publication Date: 2024-11-06OHIO STATE INNOVATION FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024112574
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-19
Filing Date
2024-07-12
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current techniques for analyzing and manipulating glioblastoma stem cells (GSCs) and myeloid-derived suppressor cells (MDSCs) are cumbersome, physiologically irrelevant, and fail to identify specific clonal subsets with high metastatic and treatment-resistant potential, making it difficult to effectively target and treat tumors like glioblastoma multiforme.

Method used

The development of therapeutic stealth cells, which are highly motile GSCs and MDSCs reprogrammed to deliver anticancer drugs, using nanotextured surfaces and chemoattractants to guide their migration and equipped with safety switches to prevent graft-versus-host disease.

Benefits of technology

These cells effectively target and destroy recurrent tumor foci by enhancing motility and delivering therapeutic agents, reducing tumor recurrence and treatment resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156704000001_ABST
    Figure 2024156704000001_ABST
Patent Text Reader

Abstract

To provide a method of reprogramming highly motile cells found in tumors, such as these highly motile GSC and / or MDSC clones, into auto-destructive cell missiles (referred to as therapeutic stealth cells) that can seek and destroy new foci of recurrence within the body, such as the brain.SOLUTION: A method for producing a therapeutic stealth cell comprises (a) sorting tumor cells from a subject for a highly motile subpopulation; and (b) reprogramming the subpopulation to deliver anti-cancer agents.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application was filed on October 19, 2018, and is incorporated herein by reference in its entirety. Priority is claimed to U.S. Provisional Patent Application No. 62 / 747,980, filed on Oct. 13, 2003.

[0002] Tumor cell metastasis is the major cause of cancer-related deaths (>90%) (Gallego-Pe rez,D.et al.Lab Chip 12:4424-4432(2012); Fidler, IJ Nat Rev Cancer 3:453-458 (2003 );Gupta,GP& Massague,J.Cell 127:679-69 5 (2006)). In particular, glioblastoma multiforme (GBM) is a highly aggressive and lethal brain tumor. (Bellail,AC,et al.Int J Biochem Cell B iol 36:1046-1069(2004)). This high-grade tumor is characterized by a distinct cranial They exhibited an intracellular diffusion pattern and effectively migrated as single cells along pre-aligned white matter tracts. (Gallego-Perez,D.et al.Lab Chip 12:4424 -4432(2012);Bellail,AC,et al.Int J Bio chem Cell Biol 36:1046-1069(2004)). invasive expression Increasing evidence indicates that GBM is regulated by cell motility (Gi J Clin Oncol 21:1624-1636(2 003)). Moreover, relapses are mainly attributable to glioma stem cells (GlS) that are resistant to conventional therapy. are caused by a subset of highly motile tumor-initiating cells known as SCs (Calabrese, C. et al. Cancer Cell 11:6 9-82(2007);Ghotra,VP,et al.Int J Radia t Biol 85, 955-962 (2009)). GSC has received great acclaim from the scientific and medical communities. The possibility that GSCs can spread and generate new tumor foci in the brain continues to attract considerable interest. New analytical and engineering tools are being developed to better understand and combat the mechanisms that cause However, studies on GSC motility and therapeutic resistance have not yet been reported. This is in part due to the unique characteristics of GSC. Certain subsets, or other cells of interest, from the GBM niche can be isolated for research, diagnosis and / or There are currently no effective tools to identify, study, and manipulate them for therapeutic purposes. Identifying tumors at the single clone level by in vivo imaging is extremely difficult (Irim ia, D. & Toner, M. Integr Biol (Camb) 1:506-51 2(2009);Condeelis, J. & Segall, JENat Rev. Cancer 3:921-930(2003)). In addition, ex vivo Current techniques for analysis tend to be cumbersome and limited (Johnson, J. et al. l.Tissue Eng Part C Methods 15:531-540(2 009)). Meanwhile, conventional in vitro assays (Boyden, SJ Exp Med 115, 453-466 (1962); Albini, A. & Benelli, R. Nat Protoc 2,504-511(2007);Rao,JSNat R ev Cancer 3,489-501(2003);Yamada,KM&C ukierman,E.Cell 130,601-610(2007);Liang, CC,Park,AY& Guan,JLNat Protoc 2,32 9-333(2007)) is not physiologically relevant and / or highly heterogeneous cells. In endpoint studies that only focus on the bulk behavior of the population be. Summary of the Invention [Problem to be solved by the invention]

[0003] There are subsets of GSCs and MDSCs that exhibit high metastatic and therapeutic resistance capabilities. However, GSCs and MDSCs are not monolithic populations, and specific clonal subsets are prominent. These findings suggest that BRCA1 expression may be more aggressive than BRCA1, possibly contributing to disease recurrence. This suggests that... [Means for solving the problem]

[0004] Disclosed herein are these highly motile GSC and / or MDSC clones. which targets highly motile cells found in tumors to seek out and destroy new recurrent lesions in the body, such as the brain. Therapeutic Stealth Cells are a type of “self-destructive” cellular “missiles” (herein referred to as therapeutic stealth cells). This is a method to "reprogram" cells with enhanced motility from a heterogeneous population. These are then used to select and then target anti-cancer drugs such as oncolytic virus-plasmid cocktails. This makes it possible to make it "self-destructive."

[0005] The disclosed method includes selecting cells from a subject to generate therapeutic stealth cells. In some embodiments, the cells may include blood cells or tumor biopsies from the subject to be treated. etc. In some cases, however, the cells are allogeneic.

[0006] The disclosed method includes sorting cells from a subject for a highly motile subpopulation and then treating the cells with an anti-cancer drug. In some embodiments, the method may include reprogramming the subpopulation to deliver the In some embodiments, subpopulations can be selected in migration assays using chemoattractant gradients. Additionally, the chemoattractant gradient may include chemokines produced by the tumor being treated. For example, in some embodiments, the chemoattractant comprises Matrigel®. In some embodiments, the chemoattractant comprises tumor cell conditioned medium.

[0007] In some embodiments, the subpopulations are nanotextured and / or biomimetic. For example, MDSCs are selected using a migration assay that uses a chromogenic surface. Under these conditions, the brain can respond to and be guided by pre-aligned structural cues. Thus, in some embodiments, the surface comprises micro- or nano-scale protrusions. For example, the depth and width of the protrusions / grooves are 100 nm to 1 μm, 1 μm to 10 μm The protrusions / grooves may have dimensions between 100 nm and 10 μm, including between 500 nm and 5 μm. They may have a variety of shapes and patterns, including straight grooves.

[0008] In some embodiments, the subpopulations are analyzed by transwell migration assays or cell invasion assays. The transwell migration assay measures the number of cells that pass through a porous membrane. On the other hand, cell invasion assays focus on invasive cell migration through the extracellular matrix. do.

[0009] Once the subpopulation has been selected and optionally expanded, the cells are then transfected with an anti-tumor protein, oligonucleotides, The recombinant vector is adapted to express a transgene encoding a polypeptide or a combination thereof. Can be programmed.

[0010] With the introduction of an efficient "safety switch," in some cases severe graft-versus-host disease can be prevented. Thus, in some embodiments, the subpopulation may also be , reprogrammed with a kill switch system. The most widely studied to date. The safety switch is the product of the HSV I-derived thymidine kinase (HSV-TK) gene. A non-immunogenic safety switch system has also been developed, which uses modified human FK506 binding tags. Human proapoptotic molecules (e.g., caspase 9) linked to protein (i.e., These safety switches contain fusion proteins composed of FK5 and iCasp9. by injection of a chemical dimerization inducer (CID) consisting of a dimer of two synthetic mutants of 06. Other inducible self-destructing kill switches are in development and disclosed. The therapeutic stealth cells can be used in

[0011] Also disclosed are compositions comprising a plurality of therapeutic stealth cells produced by the disclosed methods. In certain embodiments, the composition further comprises a pharma- ceutically acceptable excipient.

[0012] A method of treating a tumor in a subject, comprising administering to the subject an effective amount of the disclosed pharmaceutical composition. The disclosed methods can be used to treat any solid tumor. In certain embodiments, tumors can develop therapeutic stealth cells. For example, highly motile MDSCs obtained from breast cancer biopsies were It can be reprogrammed to treat breast cancer as well as glioblastoma multiforme (GBM). ) Reprogramming highly motile GSCs / MDSCs from biopsies to treat GBM This can be done.

[0013] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will become apparent from the description and drawings, and from the claims. It would be. [Brief description of the drawings]

[0014] [Figure 1A] Figures 1A-1E show the results of migration-based sorting / "chromatography". Figure 1A shows that nanotextured surfaces induce guided motility. Clones with high motility are attracted into the collection chamber by chemoattraction. Figure 1B shows that studies with GSCs reveal that highly motile clones were resistant to anti-miR363 therapy. Figure 1C shows that migration-based sorting of MDSCs revealed clonal subsets with superior motility compared to bulk MDSCs. Figure 1D shows that sorting revealed diverse phenotypes with granulocytic (P4) and monocytic (P5) subtypes. There was also an unclassified subtype showing low (P6) Ly6-C / G or high (P3) Ly6-C / G. Figure 1E shows that MDSC clones with high motility were either P4 or P3. *p<0.05. [Figure 1B] Same as above. [Figure 1C] Same as above. [Figure 1D] Same as above. [Figure 1E] Same as above. [Diagram 2]FIG. 2 illustrates the intracranial injection of reprogrammed / controlled GSCs and / or MDSCs into GBM-bearing mice and monitoring tumor progression. [Diagram 3] Figure 3 shows that MDSCs exhibit significant (i.e., guided) motility on textured / biomimetic surfaces, whereas MDSCs cultured on TCPs exhibit limited motility. These results suggest that, like tumor cells, MDSCs may respond to the same structural cues that enhance tumor cell metastasis in vivo. *p<0.05. [Figure 4A-B] Figures 4A and 4B show a migration chromatography setup where MDSCs are selectively seeded on one side of the platform and allowed to migrate unidirectionally by chemotaxis. Surface nanotexture triggers clonal separation based on guided motility. Figure 4C shows the speed of fast vs. slow migrating cells. Figures 4D and 4E include flow cytometry analysis showing that fast migrating clones have a distinct phenotype compared to slow migrating clones (e.g., bulk MDSCs). *p<0.05. [Figure 4C] Same as above. [Figure 4D] Same as above. [Figure 4E] Same as above. [Figure 5A]Figures 5A and 5B show single clone motility assays of circulating MDSCs from melanoma patients. Differences in speed (Figure 5A) and effective displacement (Figure 5B) for each patient. Results show that MDSCs from certain patients show enhanced speed. However, when considering effective displacement (i.e., geometric distance from start to end position), certain MDSC batches with low speed show significant displacement, which may reflect higher directional / sustained motility (no chemotaxis). P1: stage IIIC, tx nivolumab + surgery; P2: stage IV, tx nivolumab; P3: stage IV V600E / BRAF, tx radiation + pembrolizumab; P4: stage IV, tx nivolumab + ipilumamab; P5: stage IV, tx pembrolizumab / ipilumamab / nivolumab; P6: stage IV V600E / BRAF, treated with INF-α). [Figure 5B] Same as above. [Figure 6A] Figures 6A and 6B show that nanotextured surfaces can be used to reveal drug sensitivity not observed with standard TCP. Figure 6A shows that single clone motility assays of patient-derived MDSCs show inhibition of specific clonal subsets (mean velocity >40 μm / h) in response to ibrutinib. Figure 6B shows that single clone motility on TCPs did not reveal an effect of ibrutinib on MDSC metastasis. [Figure 6B] Same as above. [Figure 7A] Figures 7A and 7B show a migration chromatography device with integrated microfluidics to enable automated detachment of clones of interest. Figures 7C and 7D show that once migration-based separation has occurred, the intrinsic microfluidic system can be used to continuously flush cold water into place, and thermal actuation of the PINIPAM layer promotes selective detachment of MDSC clones of interest. [Figure 7B] Same as above. [Figure 7C] Same as above. [Figure 7D] Same as above. [Figure 8A] Figure 8A shows that co-culturing MDSCs with non-cancerous MCF10A enhanced motility in the MCF10A clone population. Figure 8B shows that immunofluorescence analysis shows that the co-culturing conditions caused a decrease in the expression of epithelial markers such as E-cadherin and an increase in mesenchymal markers (e.g., vimentin) in certain clones. Figure 8C shows that co-culturing MDSCs with already highly malignant MDAMB-231 cells did not significantly alter motility in the MDA-MB-231 population. ●: culture alone, ■: 50:50 co-culture, ▲: 90:10 co-culture (MDSC: breast cancer / tissue cells). [Figure 8B] Same as above. [Figure 8C] Same as above. [Figure 9] Figure 9 shows that co-culture of MDSCs with breast tissue / cancer cells resulted in a significant increase in the velocity of certain MDSC clones, especially when co-cultured with MDA-MB-231. These results potentially suggest that MDSC motility is up-regulated in the presence of metastatic cells, facilitating co-metastasis outside the tumor and continued immune protection during the tumor cell metastatic process. [Figure 10A-B]Figures 10A-10E show that MDSCs respond to aligned structural cues and display guided metastatic patterns. Figure 10A is a schematic of the tumor microenvironment showing invasive cancer cells and invasive MDSCs using pre-aligned structural cues (e.g., remodeled ECM, vascular wall) to evade and invade the tumor stroma, respectively. Figure 10B is an SEM micrograph (overlaid with MDSC mockup) of a PDMS-based biomimetic textured surface used to evaluate structurally guided MDSC migration at the single clone level. Figure 10C shows actin-nuclear staining of MDSCs cultured on textured vs. control / TCP surfaces. MDSCs adopt an aligned / more migratory morphology on textured surfaces compared to TCP. Figures 10D and 10E show single clone metastatic tracks (Figure 10D) and quantification of MDSCs (Figure 10E) on textured vs. control / TCP surfaces, confirming the enhanced metastatic potential of MDSCs (i.e., mean single clone velocity and net track distance) when exposed to pre-aligned structural cues. Net track distance reflects the geometric distance traveled by cells during the tracking period. *p<0.01 and ‡p<0.02 (t-test, n=4). [Figure 10C] Same as above. [Figure 10D] Same as above. [Figure 10E] Same as above. [Figure 11A-B]Figures 11A-11I show that MDSC subpopulations display distinct migration and gene expression patterns. Figures 11A and 11B are schematics of the experimental design. Here, MSC-2 cultures were sorted by flow cytometry into three different subpopulations, including granulocytic MDSCs (CD11b+Ly6CloLy6G+) and monocytic MDSCs (CD11b+Ly6ChiLy6G-), as well as CD11b+Ly6C+Ly6G+ cells. Each population was then subjected to single-clone motility assays on textured PDMS and qRT-PCR analysis of pro- and anti-inflammatory markers. Figure 11C shows actin-nuclear staining of different MSC-2 subtypes cultured on textured surfaces. Granulocytic MDSCs tended to display a more aligned and migratory-prone morphology compared to their counterparts. Figure 11D shows the quantification of single-clone migration (i.e., mean speed and net track distance) of each subtype on textured surfaces. *p=0.006, **p<0.001, ψp=0.001, ‡p=0.09 (2-way ANOVA, n=4). Figure 11E shows single clonal tracks for each population. Figure 11F shows fluorescently labeled flow-sorted MDSCs vs "new" / unsorted MDSCs injected (i.e., via tail vein) into tumor-bearing mice (i.e., orthotopic breast cancer developed from human cells in nude mice). Pictures on the right show tumor progression / growth from 1 to 4 weeks. Figure 11G shows tumors and other target organs imaged to detect the extent of MDSC infiltration 24 hours after injection. Figures 11H and 11I show qRT-PCR analysis of pro-inflammatory genes (Figure 11H) and anti-inflammatory genes (Figure 11I) for each subtype. *p<0.001, **p<0.0001, ‡p=0.03 (two-way ANOVA, n=3-4). [Figure 11C] Same as above. [Figure 11D] Same as above. [Figure 11E] Same as above. [Figure 11F] Same as above. [Figure 11G] Same as above. [Figure 11H] Same as above. [Figure 11I] Same as above. [Figure 12A]Figures 12A-12G show that a single MDSC subpopulation appears to exhibit phenotypic plasticity capable of driving recruitment across the entire phenotypic range. Figure 12A is a schematic of the experimental design. Figure 12B shows that single clonal migration (i.e., mean velocity and net track distance) studies showed no significant differences in all three populations by 7 days. Figures 12C-12E show that flow cytometry analysis suggests that all subpopulations remained relatively pure up to 1 day after sorting, but by 7 days, the full range of phenotypes was recruited regardless of the starting cell population. *p<0.0001, ‡p=0.01, #p=0.03, ψp=0.0001 (2-way ANOVA / Tukey's multiple comparisons, n=3-4). Figures 12F and 12G show qRT-PCR analysis of pro-inflammatory (Figure 12F) and anti-inflammatory (Figure 12G) genes at 7 days after sorting. *p=0.006, **p=0.01 (two-way ANOVA / Tukey's multiple comparisons, n=3~6). [Figure 12B] Same as above. [Figure 12C] Same as above. [Figure 12D] Same as above. [Figure 12E] Same as above. [Figure 12F] Same as above. [Figure 12G] Same as above. [Figure 13A] Figures 13A and 13B show that circulating MDSCs from melanoma patients show distinct metastatic profiles at the single clone level. Figures 13A and 13B show that the mean single clone velocity (Figure 13A) and net track distance (Figure 13B) tended to be significantly higher for certain patients compared to the rest of the patient population, which may reflect the patient background. [Figure 13B] Same as above. [Figure 14A]Figures 14A-14F show that different subpopulations of patient-derived MDSCs display distinct metastatic potential. Figures 14A-14C show that melanoma patient MDSCs were sorted by flow cytometry into granulocytic (CD11b+CD15+CD14-) and monocytic (CD11b+CD15-CD14+) subpopulations. Figures 14D-14F show that similar to the observations in mouse MDSCs, the granulocytic subpopulation of patient-derived MDSCs also displays increased metastatic (i.e., mean single clone velocity and net track distance) potential compared to the monocytic subtype. *p=0.0005, **p=0.002 (Mann-Whitney, n=3). [Figure 14B-C] Same as above. [Figure 14D] Same as above. [Figure 14E] Same as above. [Figure 14F] Same as above. [Figure 15A] Figures 15A and 15B show differential gene expression of pro-inflammatory (Figure 15A) and anti-inflammatory (Figure 15B) markers as a function of time for flow cytometry sorted subpopulations. *p<0.0001, ‡p=0.06 (2-way ANOVA / Sidak's multiple comparisons, n=3-6). [Figure 15B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Before describing the present disclosure in further detail, it is to be understood that this disclosure is not limited to particular embodiments described. Therefore, it is to be understood that variations are possible. are intended only to describe particular embodiments, and the scope of the present disclosure is limited to the appended claims. It should also be understood that the present invention is limited only by the above and is not intended to be limiting.

[0016] Where a range of values ​​is given, any limit between the upper and lower limits of the range shall be clearly stated unless the context clearly indicates otherwise. Unless otherwise stated, each intervening value is to the tenth of the lower limit, and within the stated range Any other or intervening values ​​are understood to be included within the present disclosure. The upper and lower limits of each range may independently be included in the smaller ranges, and any particular range may be included in any particular embodiment. Unless there are any excluded limits, these are also included within the scope of the present disclosure. If one or both of the limit values ​​are included, then either or both of those included limit values ​​are excluded. Such ranges are also included in the present disclosure.

[0017] Unless otherwise specified, all scientific and technical terms used herein are defined in accordance with the principles of this disclosure. The terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which they pertain. Any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of this disclosure. Although any method and material can be used, preferred methods and materials are described here.

[0018] All publications and patents mentioned herein are hereby expressly incorporated by reference. The present invention is incorporated herein by reference as if specifically and individually indicated to be incorporated in the specification. The methods and / or materials are disclosed and described in connection with the publications incorporated and referenced herein. The reference to any publication is hereby incorporated by reference as if fully set forth herein prior to its filing date. disclosure, and the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, any publication dates provided may be subject to change without notice. The actual publication dates may be different and may need to be confirmed by technical support.

[0019] As will be apparent to those of skill in the art upon reading this disclosure, the individual embodiments described and illustrated herein may Each of the embodiments may be combined with any number of other embodiments without departing from the scope or spirit of the present disclosure. Can be easily separated from or easily combined with any of the features The components and features may be individual components and features that may be combined. The method may be carried out in the order of events recited or in any other order which is logically possible. It is possible.

[0020] The embodiments of the present disclosure are, unless otherwise indicated, based on chemical , and biological technologies.

[0021] The following examples illustrate how to carry out the methods disclosed and claimed herein and how to probe These are provided to provide those of ordinary skill in the art with a complete disclosure and explanation of how to use the numerical values ​​(e.g., Efforts have been made to ensure accuracy with respect to measurements (quantities, temperatures, etc.), but some errors and deviations may occur. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20°C and 1 atmosphere.

[0022] Before describing the embodiments of the present disclosure, it is to be understood that, unless otherwise indicated, the present disclosure may vary. It should be understood that the present invention is not limited to any particular materials, reagents, reactants, manufacturing processes, or the like. Also, the terminology used herein is for the purpose of describing particular embodiments only. It should also be understood that the disclosure is not intended to be limiting. It is also possible that the steps can be executed in a different order where this is logically possible.

[0023] As used in the specification and the appended claims, the singular forms "a," "an," and "th" are used interchangeably. "e" includes multiple referents unless the context clearly indicates otherwise. Please note:

[0024] "Suicide gene," as used herein, refers to a gene that causes a cell to commit suicide by apoptosis. The activation of these genes can result from many processes, but apoptosis The main cellular "switch" that induces this is the p53 protein. Stimulation or introduction of suicide genes Using gene therapy to make cancer cells more aggressive and susceptible to chemotherapy By controlling the expression of the agonist in cancer cells, cancer or other proliferative disorders can be treated. Some of the genes expressed by the tumor can convert harmless substances into substances that are toxic to the tumor. It is linked to other genes for enzymes not found in mammals. This susceptibility mediates suicide. The gene is a virus that converts an inactive drug into a toxic antimetabolite that blocks nucleic acid synthesis. The polypeptide may encode a gene for a bacterial enzyme.

[0025] Highly motile GSC and / or MDSC clones were isolated from nanotip-supported single-clonal motile clones. They can be selected from heterogeneous populations by migration-based selection, such as chromatography. The migration-based cell sorting method identifies clones that exhibit enhanced metastatic potential compared to the rest of the population Such cells are essentially the original have a higher propensity for homing / invasion to primary tumors and / or metastatic growth, and therefore are more effective These highly metastatic clonal subsets may serve as efficient drug / gene delivery vehicles. Identifying the target can be achieved in a variety of ways.

[0026] One option is to seed the cell mixture in lines onto a micro- or nano-textured surface. This leads to contact-guided directional migration of cells. In the absence of biochemical stimuli, MDSCs respond to pre-arranged structural cues, which You can be guided along the way.

[0027] The cells can be exposed to a chemoattractant gradient that defines a particular direction in which the cells will migrate; "Fast migrating" clones move in the vessel as they migrate toward the chemoattractant. It is not possible to perform this selection in the absence of chemical attractants. In addition, they exhibited unidirectional motility (i.e., toward the collection vessel) even in the absence of chemoattractants. as a way to identify clonal subsets that may be more likely to exhibit Even though these cells are not necessarily the fastest movers, they are still The ability to exhibit persistent motility in a directional manner could translate to enhanced ability to metastasize in vivo. (For example, cells with high migration speed but lack of directionality are not necessarily the most effective "infiltrators." This also allows for the identification of these clones in the primary tumor and and / or making it desirable for enhanced drug / gene delivery to metastatic growths.

[0028] Another method for selecting cells with enhanced metastatic potential is to use a transwell system (e.g. For example, the cells can be translocated through a 100-μm hole (8 micron pore). Cells with enhanced metastatic potential can then be seeded onto the top chamber of the tube, and the cells can then migrate across the pores to form a balloon. They gradually translocate to the Tom chamber and then to the bottom chamber, where they are further modified (gene / for drug delivery applications).

[0029] As disclosed herein, the disclosed subpopulation of cells is CD11b + Ly6C lo Ly6G + Myeloid derived suppressor cells. Thus, in some embodiments, Motile cells are expressed in a combination of antibodies that selectively bind to CD11b, Ly6C, and Ly6G. The tumor-derived GSCs and / or MDSCs are obtained by cell sorting using

[0030] In some embodiments, the cells are derived from primary tumor cells (e.g., from routine biopsy specimens). In some embodiments, the cells are derived from myeloid derived suppressor cells. However, the disclosed method does not involve the detection of cancerous tissue. It can be applied to any other cell type prone to infiltration (e.g., other monocytes, T cells, etc.) can.

[0031] Once preselection of high-disseminating clones is complete, these cells can be expanded first. The transgene is then delivered either virally or non-virally (e.g., by bulk electroporation). delivery (tissue nanotransfection) and / or CRISPR / CAS9-driven The cells can be genetically engineered through a variety of routes, including the insertion of transgenes that can be used to The goal of the study is to induce the expression of anti-tumor proteins, oligos, and / or other substances (e.g. For example, glut1, mir146, oncolytic viruses, etc. Once genetic engineering of these highly motile subpopulations is complete, these cells can then be used to induce cancer proliferation. The aim is to eradicate the proliferation of The tumor can then be transferred back into the patient, either to the primary tumor or to the metastatic tumor. In morphology, the transgene encodes tissue inhibitor of metalloproteinase-3 (TIMP-3). Convert it to a PDF file.

[0032] For cancer applications, these cells can be engineered (via transfection) to suppress inflammation Inducible molecules (e.g., CCL4, MIR146, Glut1) are expressed to induce tumor or anti-tumor Promoting T cell infiltration into metastatic sites (e.g., timp3) to prevent cancer metastasis can.

[0033] In some embodiments, MDSCs are used to deliver anti-inflammatory molecules to treat Alzheimer's disease. in other conditions such as diabetes or other forms of brain injury (e.g., ischemic stroke) A therapy is administered, in which MDSCs naturally home to the tumor and once activated, promote angiogenesis and / or or pre-neural, or therapeutic cargo such as anti-inflammatory drugs.

[0034] These autologous cells are then drug-induced (e.g., doxycycline) before being injected back into the patient. Lin) By further manipulating the "kill switch" system, the action of the therapeutic cells was no longer necessary. Kill switch systems are known in the art and can be used to eradicate them. Therefore, it is within the purview of one skilled in the art to select and employ a suitable kill switch system. .

[0035] A number of embodiments of the present invention have been described. Nevertheless, it should be understood that certain modifications and variations may be made without departing from the spirit and scope of the present invention. It is understood that various modifications can be made without departing from the spirit and scope of the present invention. It is within the scope of the following claims. EXAMPLES

[0036] Example 1: Nanoengineered Therapeutic Stealth Cells The metastatic potential of GSCs and their ability to evade the immune system or standard treatments remain major concerns. Nanoscale tools can be used to improve metastasis and treatment resistance. We isolated and studied specific subsets of GSCs as shown (Figure 1).

[0037] In addition, pilot studies using MDSCs demonstrated that, like GSCs, they have a significant metastatic potential. These findings are consistent with those of GSC and MD. SCs are not a monolithic population, and specific clonal subsets are likely These results suggest that patients with BRCA1-positive ...negative ovarian cancers exhibit a significantly more aggressive phenotype that may lead to disease recurrence. This example discloses the use of highly motile GSC and / or MDSC clones. The cells are then reprogrammed into "self-destructive" "missiles" that can seek out and destroy new recurrent lesions in the brain. A novel high-risk / high-return strategy to minimize GBM recurrence by ramming The aim of this study is to develop a novel approach to the development of GSCs and MDSCs with enhanced motility. Thus, nanotip-assisted single-clone motility "chromatography" can be used to isolate single clones from heterogeneous populations. These cells are then subjected to limited clonal expansion (2-5 passages) This was followed by definitive nanochannel-based delivery of the oncolytic virus-plasmid cocktail ( Gallego-Perez, D. et al. Nanomedicine 12:39 These viruses are known to be “self-destructive” by the HIV-1 virus, which is a type of virus that causes infection with conventional medicine. GSCs can kill cancer cells by a different mechanism than the normal cell death mechanism. It has been proposed as a promising treatment option for eradicating Mol Ther 17:1677-1682(2009)).

[0038] A series of in vitro tests were performed to confirm that GSCs or MDS cells retained excellent motility over a long period of time. Determine the optimal plasmid dose and ratio for which a selected subgroup of C is “self-destructive.” These “controlled” but highly motile GSC / MDSC populations are then cultured in a 30-well plate. M mice, effectively translocating and strategically releasing therapeutic virions throughout the diseased brain. Intracranial injections (together and separately) are performed with the aim of releasing the

[0039] We also performed comparative experiments on systemic delivery of reprogrammed / drug-modified MDSCs to confirm whether these cells could be used to treat disease. Verify that the cells can home to the affected brain and disrupt tumor progression To achieve this, studies will be performed in GBM-bearing mice. T, MRI) will be used to monitor the outcome of therapeutic GSC / MDSC. Oncolytic virus therapy of the tumor is more effective than direct therapy with oncolytic virus particles. Promising results have been shown previously (Power, AT&Bell, JCMol Ther 15:660-665(2007)), the main limitation is that Most of the cells isolated have poor metastatic potential, especially when compared with the intracranial metastatic pace of GSCs. On the other hand, controlled / reprogrammed GSCs or MDSCs suppress the immune response. In addition to their stealth capabilities against the system, they may have inherently high intracranial mobility and therefore These could be colonized, making it possible to more effectively monitor and treat diseased brains. Example 2: Structurally guided translocation of mouse MDSCs

[0040] Recent studies have demonstrated that MDSCs are able to form pre-aligned structural cues in the absence of biochemical stimuli. It has been shown that the brain responds to pre-aligned structural cues and can guide the brain along them ( In contrast, single-clonal motility on tissue culture polystyrene (TCP) was The efficacy assay revealed low metastatic potential (Figure 3), suggesting that, similar to tumor cells, MDSC metastasis / These results suggest that invasion is probably favored by structurally guided migration. The migration chromatography studies demonstrated a residual population of cells that represents high-grade cancer cells. We identified a subset of clones with enhanced metastatic potential compared to controls (Figures 4A-4C). Flow cytometric analysis of fast-migrating clones revealed that such populations were predominantly Ly 6-G high / Ly6-C low (granulocytes) and Ly6-G high / Ly6-C hi gh (unspecified). The phenotype of the slow-migrating clones was similar to that of monocytes ( Ly6-G low / Ly6-C high ) and granulocytes, as well as the unidentified variant Ly6 -G low / Ly6-C low and Ly6-G high / Ly6-C high More between Thus, MDSCs are clearly specialized clones with improved metastatic potential. The study also found that the IL-16 expression vector has a lone subset of IL-16 that likely colonizes tumors / ganglia and exerts immunosuppression. Such clonal subsets are therefore likely to play a key role in the fight against cancer. These drugs may be novel therapeutic targets. Example 3: Structurally guided transfer of patient MDSCs

[0041] Second, patient-derived MDSCs also exhibited structurally guided migration in the absence of biochemical cues. We examined whether peripheral blood flow to the melanoma cells of patients with different stages of melanoma under different treatments was associated with a favorable outcome. MDSCs isolated from blood were followed for approximately 24 hours. Each patient's MDSCs showed a unique metastatic pattern. Some patients showed clonal subpopulations with enhanced mobility compared to the bulk population. A subset of the spheroids (Fig. 5) remained clustered at less than 25 μm / h. In addition, some patients had MDSCs that were clustered together globally with a velocity of <25 μm / h. These results suggest that the tumours may be involved in the development of malignant tumors, possibly representing a seemingly "quiescent" population. reflects the type and / or mode / stage of therapy. These factors and MDS may serve as surrogates for their levels of disease outcome. Further studies to establish a clear correlation between the single clonal metastatic potential / signature of C. Although further studies are needed, these data suggest that MDSCs are not monolithic and that motility Investigating sex-related mechanisms could potentially lead to improved therapies as well as new Further supporting the idea that this could pave the way for the development of diagnostic / prognostic tools. Example 4: Structurally guided migration reveals drug sensitivity

[0042] Impairing MDSC migration / infiltration into tumors / ganglions is an effective treatment to reduce the immunosuppressive burden. Inhibitors of Bruton's tyrosine kinase (BTK) are typically administered intravenously to It has been used in the treatment of cancer. BTK plays a role in many biological processes, including cell migration. MDSCs express BTK, but in the presence of ibrutinib (a BTK inhibitor), Single clone motility assays of TCPs showed no significant effect on migration. In contrast, motility assays on biomimetic surfaces showed that MDS These results appear to indicate selective targeting of a highly motile subset of C. Results show that migration-driven changes (e.g., cytoskeleton alignment) are essential for MDSCs These results indicate that the drug sensitivity in Example 5: A biomimetic platform for migration chromatography

[0043] In-house nanofabrication expertise (i.e. contact / projection-based lithography) - and soft lithography - to fabricate polydimethylsiloxane (PDMS) Pre-aligned structural cues (approximately 300 nm wide) are fabricated. The textured surface is then Then, the thermoresponsive polyimide was deposited under argon plasma (30 watts, approximately 1000 microTorr). Functionalized with N-isopropylacrylamide (PNIPAM). The coated substrate (approximately 100 μm thick) was then subjected to The microfluidic system (width 50 μm, pitch 500 μm, independently operated, Figure 7) was connected to the These channels are used to selectively inject cold water underneath the textured PDMS. Selective cell detachment from PINIPAM by thermal activation (i.e., from weakly hydrophobic The nanotextured surface was characterized by scanning electron microscopy (SE The PNIPAM coating was characterized by TEM and atomic force microscopy (AFM). The measurements were carried out using contact angle measurements at different temperatures, X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy. It is verified by light (FTIR). Example 6: MDSC Motility

[0044] MDSCs were cultured in breast cancer tumors under protocol OSU-09142 using standard procedures. It is isolated from freshly obtained tissues from the patient (ie peripheral blood, tumor and lymphoid tissues). Tumor cells / tissues are also harvested using standard procedures36. Migration Chromatography used GM-CSF (200 ng / mL) as a chemoattractant to induce biomimetic The results are performed on a 3D surface (Figures 4, 7). Different sources of MDSC (i.e., circulating vs. tumor v s Lymphoid tissue-resident) single clone migration was measured using a confocal microscope equipped with a culture chamber. Time-lapse microscopy was performed with a microscope. Images were collected every 10 minutes for 24-72 hours. Collect and post-process / analyze using a manual tracker plugin in Fiji. MDSC clones exhibiting different degrees of motility were cultured in the microchannels of the platform. Cells are isolated by selectively "manipulating" the These clones are classified as highly motile, intermediately motile, or low motile depending on the phenotype (Figure 7). The biomechanics of the subsets (i.e., stiffness and contractility) were then evaluated using single-cell adhesion assays, as described below. Vibration, a technique developed by Co-I Ghadiali to analyze elastic properties The results are analyzed by dynamic AFM and traction force microscopy (TFM). The lysosomes were isolated from monocytes (CD15 + / CD14 + ) and granulocytes (CD15 + / CD14 - )marker Immunosuppressive activity of each clonal subset will be investigated. To assess the efficacy of T cell proliferation, we cultured T cells (at different concentrations) with CFSE-labeled T cells. Cell proliferation was assessed by flow cytometry. L peptide was used as a negative control and a positive control, respectively. Finally, the strongest inhibitory activity was The clonal subsets that have the genomic DNA sequence were further characterized by single-cell sequencing, as described below. Analyze. Example 7: BTK Inhibition

[0045] Once high migration and / or immunosuppressive clones have been identified from different source MDSCs, The extent to which a TK inhibitor (i.e., ibrutinib) interferes with guided metastasis will be evaluated. First, immunoblotting was used to determine whether each clonal subset responded to 0–10 μM ibrutinib. The levels of exposed BTK and phosphorylated BTK (p-BTK) were evaluated. The subset was then seeded (approximately 10 3 ~10 4 cells / cm 2 ), Guided migration was monitored by time-lapse microscopy while exposed to 0–10 μM ibrutinib. The images are processed and analyzed by Fiji. ACP-196 (selected and irreversible BTK inhibitor) and GDC-0853 (selective and reversible BTK inhibitor) For comparison purposes, experiments using ibrutinib will be performed again using AFM and TFM. Use these methods to assess single cell stiffness and contractility, respectively. MDSC Motility and Biomechanics The effect of BTK inhibition on gliomas was investigated in an open study conducted at OSU with support from the OSU CCC. Breast cancer patients who received ibrutinib under the support of a clinical study (OSU-18015) After obtaining informed consent, 30cc of peripheral blood was collected from the patient before and after treatment. MDSCs were isolated and analyzed for their monoclonal motile and viability. The mechanical properties (i.e., AFM and TFM) are evaluated as previously described. Example 8: Reciprocal regulation of MDSC / tumor cell metastasis

[0046] Preliminary studies have demonstrated that MDSCs are specialized clonal subsets with improved mobilization. This is probably due to the fact that it colonizes the tumor / lymphoid tissue or coexists with highly invasive tumor cells. It has been shown to be prone to synchronous metastasis and to provide "protective" immunosuppression during the early stages of metastasis. Pilot studies on mimetic surfaces (Figures 8-9) demonstrated that the presence of MDSCs Enhanced motility of epithelial to mesenchymal transition in a clonal subset of noncancerous breast tissue cells It was shown that MDSCs were able to induce metastasis in healthy tissues (Figures 8A-8B). These results suggest that MDSCs may have the ability to induce localized cancerous changes. However, it did not appear to induce significant changes in the overall motility patterns of highly aggressive breast cancer cells. Interestingly, the most aggressive tumor cells were characterized by a single clone in MDSCs. The strongest changes in cell motility were induced by MDSCs at around / below 40 μm / h (Figure 9). From single clone rastering speeds, to speeds that can reach up to about 100 μm / h in some cases and possible involvement of enhanced cytokine / chemokine secretion from high-grade tumor cells. Highly sexual. Example 9: Tumor-associated bone marrow-derived IgG4-dependent clonal migration studies at single clone level Suppressor cell populations reveal interesting potential therapeutic targets

[0047] method

[0048] Textured PDMS Surface: Microtextured PDMS surfaces are suitable for replica molding. The process was fabricated from a photolithographically patterned silicon master. The parallel arrangement of protrusions and grooves (width 2 μm, height 2 μm, 2 μm intervals) was first fabricated using S1813 photoresist. Patterns are then printed on a silicon master by standard UV photolithography using a resist. A 10:1 mixture of PDMS and curing agent was then cast onto the master and allowed to dry for several hours. The PDMS was then demolded from the master and prepared for single cell migration experiments. The surface morphology was analyzed using scanning electron microscopy (SEM). characterized.

[0049] MDSC culture: Mouse MDSC cell line (MSC-2) was developed by Gregoire Mignon MSC-2 cells were cultured in 25 mM HEPES, 10% heat-inactivated fetal bovine serum. Supplement with fetal bovine serum (FBS), 1% antibiotic-antimycotic, and 1 mM sodium pyruvate. Patient-derived MDSCs were cultured in RPMI 1640 medium containing RosetteSep Using HLA-myeloid cell enrichment kit (Stemcell Technologies) and enriched from peripheral blood using Ficoll-Paque centrifugation (GE Healthcare MDSCs were then implanted with anti-HLA-DR MicroBeads (Milcare). Negative immunoprecipitation of HLA-DRneg cells using a ELISA kit (Tenyi Biotec) for 15 min at 4°C. The samples were isolated by selection and separated using an MS-MACS column. Informed consent was obtained under an IRB-approved protocol.

[0050] Single cell migration assay: approximately 1.5 x 10 5 MSC-2 cells were seeded and incubated in normal medium. Cells were seeded onto the textured PDMS surface or TCP control and allowed to adhere for several hours. The cells were cultured for 16 hours using a cell culture chamber (Okolab) attached to a microscope. The images were taken every 10 minutes using time-lapse microscopy. The single cell displacement data were then analyzed using a manual tracker. The velocity and net track distance traveled were determined.

[0051] Flow cytometry-based analysis and sorting: The following antibodies were used for MSC-2 cells: Anti-CD11b-FITC, anti-Ly6-C-APC and anti-Ly6-G-PE, all For patient-derived MDSCs, we purchased them from Beckman Biolegend. Anti-CD33-APC, anti-CD11b-AP, and anti-HLA- DR-PECy7 was used. Data were analyzed using an LSRII flow cytometer (BD Biosciences, Inc.). All colors were compared with their respective isotype controls and The stained and unstained samples were evaluated.

[0052] Gene expression analysis: Total RNA was analyzed using TRizol reagent (ThermoFisher). The reverse transcription reaction was performed using the SuperScript VILO cDNA Synthesis Kit (Th Use 500-1000ng of RNA in a 20μl reaction in the ERmoFisher The cDNA was used as a template and pre-designated primers were used to The expression levels of pro- and anti-inflammatory genes were measured by quantitative real-time PCR using Real-time PCR reactions were performed using a QuantStudio 3 real-time PCR system. stem and TaqMan fast advance chemistry (Therm o Scientific) under the following conditions: 95°C for 10 min; 40 cycles of 1 min at 40°C, 1 min at 60°C, and 1 min at 72°C. Normalized to the binding genes GAPDH and ATP-6.

[0053] Orthotopic tumor xenografts: Immunodeficient nude mice (Jackson Laboratory ), 6-8 weeks of age, first inoculated 1 million human breast cancer cells (MDA-MB) into the mammary fat pad. -231) to allow tumor formation. Four weeks after tumor formation, selected MDSCs were Subpopulations were analyzed using the PKH67 green fluorescent cell linker kit (Millipore) for general cell membrane labeling. re Sigma) according to the instructions suggested by the manufacturer. Next, tumor-bearing mice were treated with approximately 2.5 × 10 5 MDSCs were injected via the tail vein. Mice were harvested 2 days later and tumors, lungs, and spleens were imaged using an IVIS Imaging System. (Xenogen Imaging Technologies). Animal studies were approved by the Ohio State University Laboratory Animal Care and Use Committee. The protocol was followed.

[0054] Statistical analysis: Perform all statistical analyzes using Sigma Plot 12 or GraphPad Pris The experiments were carried out at 7 m. We used n = 3–6 replicates per experiment. The number of replicates, statistical tests, Specific information regarding levels of significance and significance can be found in the figure legends.

[0055] Results and Discussion

[0056] MDSCs respond to topographical cues and display structurally guided metastatic patterns Structurally guided cell metastasis is a promising strategy for the escape of cancerous cells from primary tumors and their migration to peripheral organs. It is known to play a role in the establishment of metastatic growth in organs and tissues. Cancer cells specifically target the extracellular matrix (ECM), white matter tracts, the basement membrane of blood vessels, and Pre-aligned fibrils in tissue, including radially oriented fibrils from the subpial / subperitoneal space These cells tend to show distinct diffusivity patterns, preferentially diffusing along anatomical microstructures. (Figure 10A) (Gallego-Perez D, et al. Lab Chip 2012,12:4424-4432;Bellail AC,et al.Int J Biochem Cell Biol 2004,36:1046-1069; Jo hnson J, et al.Tissue Eng Part C Methods 2009,15:531-540). Using micro- and nano-scale tools, These are used to theoretically probe cancer cell motility under physiologically relevant conditions. We have developed a system that can .Lab Chip 2012,12:4424-4432;Bellail AC,e t al.Int J Biochem Cell Biol 2004,36:104 6-1069;Johnson J,et al.Tissue Eng Part C Methods 2009,15:531-540;Irimia D,et al. Integr Biol(Camb)2009, 1:506-512;Doyle A D,et al.J Cell Biol 2009,184:481-490;Pet rie RJ, et al.Nat Rev Mol Cell Biol 2009 ,10:538-549). Although topographical or cell-localized cues have been used to mimic o-Perez D,et al.Lab Chip 2012,12:4424-44 32;Johnson J,et al.Tissue Eng Part C Met hods 2009,15:531-540;Irimia D,et al.Inte gr Biol(Camb)2009,1:506-512;Sidani M,et al.J Mammary Gland Biol Neoplasia 2006,1 1:151-163;Provenzano PP,et al.BMC Med 20 06,4:38;Wong IY,et al.Nat Mater 2014,13: 1063-1071), and the influence of such cues on the metastatic / invasive potential of tumor-associated MDSCs. There are no studies examining the effect of MDSCs on the proliferation and proliferation of invasive cancer cells. , which respond to topographical cues by exhibiting structurally guided migration patterns. The murine MDSC cell line, MSC-2, was used as a model (S tiff A,et al.Cancer Res 2016, 76:2125-21 36;Trikha P,et al.Oncoimmunology 2016,5: e1214787). These cells were then grown on silicon masses created using photolithography. The cells were fabricated from a 3D printer via replica molding and were sized to the dimensions previously tested in cancer cell metastasis studies (approximately 2 μm The micropattern was designed as an array of parallel projections and grooves with a diameter of 2 μm x 2 μm, spaced 2 μm apart. (Ga) llego-Perez D,et al.Nano Lett 2016,16:53 26-5332;Gallego-Perez D,et al.Lab Chip 2 012,12:4424-4432;Kim SH,et al.Cancer Cel l 2016,29:201-213;Gu SQ,et al.Nucleic Ac ids Res 2016,44:5811-5819). The cells were monitored in real time at the cell level by time-lapse microscopy. Cells seeded on culture surfaces (i.e., tissue culture polystyrene or TCP) were used for comparison purposes. The results showed that MDSCs exhibited limited motility on TCP at the single clone level. 10C-10E), and most of the cells exhibited a rounded morphology (Fig. 10C). On the other hand, textured surfaces induced cytoskeletal and morphological rearrangements in some MDSCs. (i.e., alignment) (Fig. 10C), which corresponds to increased motility. The average single clone velocity on the TCP was approximately 20 μm / h. A maximum value of about 40 μm / h was reached on the textured surface compared to the normal surface. The net track distance, a measure of effective displacement, is <100 μm on the textured surface compared to <100 μm on the TCP. On the textured surface, a maximum value of about 400 μm was reached over a period of 16 hours. MDSCs migrating on charred surfaces showed significant interclonal variability in metastatic potential However, cells ranged from low to high motility. In contrast, cells migrating on TCP Circulating MDSCs derived from cancer patients showed significantly lower interclonal variability. (Figure 13) demonstrated the presence of a highly motile MDSC population that showed marked interclonal variability. Further confirmation revealed that some clones were approximately 200 μmh -1 Average guided migration speed up to showed a total net displacement approaching 1 mm over a 16-hour period. Certain populations of circulating MDSCs derived from MDSCs exhibit limited overall motility, which may potentially may be a direct reflection of the primary malignancy (e.g., type, stage, mutation) and / or Current treatments (Tables 1-3). [Table 1] [Table 2] [Table 3]

[0057] MDSC subpopulations display distinct metastatic potential. Based on clear interclonal variability in motility, Based on the standard MDSC nomenclature, we have classified granulocytes (CD11b + Ly6C lo Ly6G + ) and monocytes (CD11b + Ly6C hi Ly6G - ) Flow cytometry for subpopulations We further stratified and probed MDSC populations by cytometry-based sorting (Figures 11A-11C). C)(Bronte V,et al.Nat Commun 2016,7:1215 0). CD11b + Ly6C + Ly6G + Subpopulations of cells were also identified using flow cytometry. Flow-sorted subpopulations were then identified from the data and included in our analysis. In addition to qRT-PCR analysis of anti-inflammatory markers, as previously described, the textured surfaces The single clone metastasis studies were performed using isolated When CD11b is expressed, granulocytic MDSCs are expressed in monocytic MDSCs and CD11b + Ly6C + Ly6G + The subpopulations had superior metastatic potential (Figure 11D), and single clones occasionally Over a period of time, an average velocity and net displacement of >100 μm / h and approximately 1.5 mm were reached. The results also showed that monocytic MDSC and CD11b + Ly6C + Ly6G + One in the subpopulation Some clones show a relatively high average migration speed of about 50 μm / h, but the net displacement is quite limited. Thus, these cells have a very short range and / or no migration compared to granulocytic MDSCs. These observations suggest that the cells tend to show an orderly motility pattern (Fig. 11E). The results were further confirmed by in vivo studies (Figures 11F and 11G), in which tumor-bearing Mice were systemically injected with fluorescently labeled suspensions of sorted vs. "new" / unsorted MDSCs and I VIS was used to document MDSC accumulation within the tumor niche vs. peripheral organs / tissues. Mice injected with MDSCs showed more prominent fluorescent signal accumulation within the tumor (Figure 11 G). Parallel single clone motility studies with circulating MDSCs from cancer patients (Figure 14) were also performed. Also, the granulocyte subpopulation (CD11b + CD15 + CD14 - ) is a monocyte subpopulation (CD11b + C D15 - CD14 + These results suggest that the inflammatory response of the mitochondrial cells to inflammatory cytokines is enhanced compared to the control cells. MSC-2 cell gene expression analysis of the “fresh” (i.e., unsorted) MDSC population and purified granulocytes, monocytes, and CD11b + Ly6C + Ly6G + Between subpopulations There were no statistically significant differences in the expression of TNF-α, iNOS, and IL-27. However, IL-6 was significantly increased in the fresh population vs. the flow-sorted subpopulation. On the other hand, gene expression analysis of anti-inflammatory markers revealed that flow-sorted granules New flow-sorted monocyte subpopulations were MDSC and CD11b + Ly6C + Ly6G + The IL-10 and arginase subpopulations were shown to be more likely to overexpress arginase and IL-10 compared to the control subpopulation. Taken together, these results suggest that the granulocytic MDSC subpopulation may be involved in the proliferation and proliferation of cancerous tissues. Not only are they easy to colonize, but they also express monocytic MDSCs and CD11b + Ly6C + Ly6G + subpopulations appear to be more likely to overexpress anti-inflammatory / inhibitory markers than This suggests that there is.

[0058] MDSC subpopulations display phenotypic plasticity that drives population homeostasis under long-term culture conditions The different subpopulations of granulocytic and monocytic MDSCs in MSC-2 cells, as well as CD 11b + Ly6C + Ly6G + Following flow-based purification of cells, cells are cultured for 1–7 days. Phenotypic plasticity was assessed by flow cytometry on days 1 and 7. Single clone motility assays and gene expression analysis were performed on day 7 (Figure 12A). Surprisingly, and in contrast to what we found immediately after flow-based sorting; No significant differences were detected in metastatic characteristics across all three populations by day 7 ( (Figure 12B). The average single clone velocity for all populations was approximately 50 μmh -1 Stay within Meanwhile, the overall net track distance remained below about 200 μm. Cytometric analysis revealed that after 1 day of sorting, the purified population still comprised the majority of the culture (approximately 8 0%), but by day 7, the entire hierarchy of the population was shown to be re-established (Figure 12 C-12E), possibly maintaining population homeostasis / heterogeneity in MDSC populations This suggests a role for cellular plasticity in the differentiation of granulocytes. , e.g., monocytes, MDSCs and CD11b + Ly6C + Ly6G + Cells give rise to monocytes The subpopulation showed the steepest increase from days 1 to 7 (approximately 7-fold change), CD11b + Ly6C + Ly6G + The population showed an approximately three-fold increase by day 7. Cultures showed a CD11b + Ly6C + Ly6G + Clean up the group Finally, purified CD11b + Ly6C + Ly6G + Population-derived cultures were more likely to give rise to granulocytic MDSCs up to day 7 compared with monocytic MDSCs (approximately 3-fold increase), which did not show a significant increase between the first and seventh days. Gene expression profiles of pro-inflammatory markers (Fig. 12F) and anti-inflammatory markers (Fig. 12G) in The pool shows more subtle differences across populations and is a “new” group compared to the selected / purified subpopulations. " showed increased and decreased iNOS and IL-6 expression, respectively, in the MDSC population. However, comparing the expression profiles between day 0 (i.e., the day of selection / purification) and day 7 In comparison, the difference was more pronounced, with proinflammatory iNOS expression in all three populations. There was an overall increase in arginase 1 and Il-10 in the granulocyte subpopulation only. A little (Figure 15).

[0059] Micro- and nanoscale techniques are investigating various aspects of cell biology and / or their application in medicine. or has been widely used to regulate .Nano Lett 2016,16:5326-5332;Gallego-Per ez D,et al.Lab Chip 2012,12:4424-4432;Ki m SH,et al.Cancer Cell 2016,29:201-213;G u SQ,et al.Nucleic Acids Res 2016,44:581 1-5819;Minata M,et al.Cell reports 2019, 26:1893-1905;Shukla VC,et al.Trends in b iotechnology 2018,36:549-561;Benavente-B abace A,et al.Biosens Bioelectron 2014,6 1:298-305;Fei Z,et al.Analytical Chemist ry 2013,85:1401-1407;Chang L,et al.Small 2016,12:5971-5980;Chang L,et al.Lab Chi p 2015,15:3147-3153;Gallego-Perez D,et a l.Biomed Microdevices 2012,14:779-789;Ga llego-Perez D, et al. Nanomedicine 2016,12 :399-409;Gallego-Perez D,et al.Nature na notechnology 2017,12:974; Wu Y,et al.Sma ll 2013,9:2358-2367;Zhao X,et al.Advance d Science 2015,2;Zhao X,et al.Anal Chem 2015,87:3208-3215). Using micro-scale engineering tools Using this technique, we demonstrated that tumor-associated MDSCs exhibited structurally guided migration patterns similar to those of invasive cancer cells. Single clone motility assays demonstrated that MDSCs exhibited a specific motility profile within and across MDSC populations. Clear heterogeneity was evident across the population (i.e., for patient-derived MDSCs), Enhanced metastatic potential in both murine-derived and patient-derived MDSCs A flow cytometry-based study in nude mice confirmed the presence of a cytotoxic subset of Selection, gene expression analysis, and motility tracking studies coupled with orthotopic tumor xenograft experiments Granulocyte subpopulations are likely to exhibit increased metastatic and tumor-infiltrating capabilities, as well as enhanced anti-inflammatory activity. Therefore, this population may represent an attractive therapeutic target in cancer. However, subsequent studies have demonstrated the striking dynamics of such clonal subsets. The purified MDSC subpopulations reveal the specific and plastic nature of MDSC expression. Tumor-resident MDSCs rapidly achieve collective homeostasis by giving rise to a type Although there are conflicting reports regarding the dominant phenotype of IL-1 (i.e., granulocytic vs. monocytic) (Kumar V,et al.Trends in immunology 2016,37:208 -220;Hossain F, et al.Cancer immunology research 2015,3:1236-1247;Haverkamp JM,e t al.European journal of immunology 2011 ,41:749-759;Mairhofer DG,et al.Journal o f Investigative Dermatology 2015,135:278 5-2793;Bozkus CC,et al.The Journal of Im munology 2015,195:5237-5250), our single clonal metastasis The consequence of this phenotypic plasticity is that granulocytic MDSCs likely have a role in infiltrating the tumor niche. We point out a potential mechanism that may be better prepared by the C may then remain granulocytic and / or monocytic, depending on several factors including tumor type. Interestingly, a single clone was used to generate circulating MDSCs from cancer patients. MDSC motility is dependent on patient background (e.g., cancer type / stage), These may potentially be affected by various factors (e.g., drugs, treatments, etc.) and therefore may be circulating ex vivo. The metastatic patterns of MDSCs can be used to monitor disease and / or treatment progression. These results suggest that further studies are needed to determine whether

[0060] Unless otherwise specified, all technical and scientific terms used herein are understood to be within the meaning of the present invention. The terms used herein have the same meaning as commonly understood by a person skilled in the art to which the invention pertains. Publications mentioned therein and the material cited therein are specifically incorporated by reference.

[0061] Those skilled in the art will recognize many equivalents to the specific embodiments of the invention described herein. Such equivalents may be readily ascertainable using no more than routine experimentation. , are intended to be encompassed by the scope of the following claims.

Claims

1. 1. A method for producing therapeutic stealth cells, comprising: (a) sorting tumor cells from a subject for a highly motile subpopulation; and (b) reprogramming said subpopulation to deliver an anti-cancer drug. 。

2. 13. The method of claim 1, wherein the subpopulation is selected in a migration assay using a chemoattractant gradient. The method described above.

3. The subpopulations are monitored by migration using nanotextured and / or biomimetic surfaces. The method of claim 1 or 2, wherein the selection is performed in an assay.

4. The subpopulations were analyzed in a transwell migration assay or a Boyden chamber assay. The method according to any one of claims 1 to 3, wherein the selection is performed based on the above.

5. The subpopulation is then subjected to a ELISA using a nucleic acid encoding an anti-tumor protein, an oligonucleotide, or a combination thereof. The method according to any one of claims 1 to 4, further comprising reprogramming the host cell to express a heterologous transgene.

13. The method according to claim 1.

6. The transgene encodes tissue inhibitor of metalloproteinase-3 (TIMP-3). The method of claim 5 ,

7. Any of claims 1 to 6, wherein the subpopulation is reprogrammed with a kill switch system.

3. The method according to claim 1 .

8. The subpopulation is CD11b + Ly6C lo Ly6G + Myeloid-derived suppressor cells, The method according to any one of claims 1 to 7.

9. The method of claim 8, wherein the subpopulation is sorted by flow cytometry.

10. A method for producing a plurality of therapeutic stealth cells according to any one of claims 1 to 9. A composition comprising a cell.

11. The composition of claim 10 further comprising a pharma- ceutically acceptable excipient.

12. 12. A method of treating a tumor in a subject, comprising administering to the subject an effective amount of the combination of claim 11. The method comprises administering a composition comprising:

13. The method of claim 12, wherein the tumor is breast cancer.